United Therapeutics (BSP:U2TH34) Current Accrued Expense: R$2,551 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
94 GF Score
Price R$127.00
GF Value R$109.27
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Current Accrued Expense?

United Therapeutics BSP:U2TH34 94 Current Accrued Expense is R$2,551 Mil as of Jun. 2026. GuruFocus rates BSP:U2TH34 with a GF Score™ of 94/100 and a GF Value™ of R$109.27. The stock has 3 warning signs investors should review.

United Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was R$2,551 Mil.

United Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 (R$2,624 Mil) to Mar. 2026 (R$2,606 Mil) and declined from Mar. 2026 (R$2,606 Mil) to Jun. 2026 (R$2,551 Mil).

United Therapeutics's annual Current Accrued Expense increased from Dec. 2023 (R$1,433 Mil) to Dec. 2024 (R$2,065 Mil) and increased from Dec. 2024 (R$2,065 Mil) to Dec. 2025 (R$2,624 Mil).

United Therapeutics Current Accrued Expense Related Terms

United Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Current Accrued Expense Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 965.86 1,184.41 1,432.70 2,065.19 2,623.65

United Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,395.79 2,509.88 2,623.65 2,605.91 2,550.78
BSP:U2TH34
94GF Score
United Therapeutics Corp BSP:U2TH34
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of R$2,551 Mil mean?
United Therapeutics (BSP:U2TH34) has a Current Accrued Expense of R$2,551 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Current Accrued Expense too high?
United Therapeutics' current Current Accrued Expense is R$2,551 Mil. Overall, United Therapeutics has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Current Accrued Expense compare to VTRS and NBIX?
United Therapeutics' Current Accrued Expense of R$2,551 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on United Therapeutics and its competitors. United Therapeutics's current Current Accrued Expense is R$2,551 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
United Therapeutics (BSP:U2TH34) has a current Current Accrued Expense of R$2,551 Mil. The stock's GF Value™ is R$109.27, compared to a current price of R$127.00 — trading 16.2% above its estimated fair value. The current Current Accrued Expense is R$2,551 Mil. United Therapeutics' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Current Accrued Expense is R$2,551 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$127.00 is trading 16.2% above its estimated GF Value™ of R$109.27.

Key valuation signals for BSP:U2TH34:

  • Current Accrued Expense: R$2,551 Mil
  • GF Value™: R$109.27 vs. price of R$127.00 (16.2% above fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
94GF Score

Get the complete analysis for BSP:U2TH34

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$127.00
Price
R$109.27
GF Value